1 Derivation and Internal Validation of Prediction Models for

2 Pulmonary Hypertension Risk Assessment in a Cohort

3 Inhabiting Tibet, China

4 Authors

- 5 Junhui Tang^{1†}, Rui Yang^{2†}, Hui Li¹, Xiaodong Wei¹, Zhen Yang¹, Wenbin Cai¹, Yao
- 6 Jiang¹, Ga Zhuo¹, Li Meng¹, Yali Xu^{3*}
- 7 Junhui Tang[†] and Rui Yang[†] contributed equally to this work.

8

9 Affiliations

- 10 1. Department of Ultrasound, the General Hospital of Tibet Military Command, Tibet, China
- 11 2. Department of High Mountain Sickness, the General Hospital of Tibet Military Command,
- 12 Tibet, China
- 13 3. Department of Ultrasound, Xinqiao Hospital, Army Medical University, Chongqing, China
- 14

15 Corresponding author *

- 16 Yali Xu, MD, PhD
- 17 Department of Ultrasound, Xinqiao Hospital, Army Medical University, 83 Xinqiao Main Street,
- 18 Shapingba District, Chongqing, 400037, PR China.
- 19 E-mail address: xuyali1976@163.com

20

21 Abstract

Background: Due to exposure to hypoxic environments, individuals residing in plateau regions
are susceptible to pulmonary hypertension (PH). Consequently, there is an urgent need for a
simple and efficient nomogram to assess the risk of PH in this population.

25 Methods: This study included a total of 6,603 subjects, who were randomly divided into a 26 validation set and a derivation set at a ratio of 7:3. Optimal predictive features were identified 27 through the least absolute shrinkage and selection operator regression technique, and nomograms 28 were constructed using multivariate logistic regression. The performance of these nomograms was 29 evaluated and validated using the area under the curve (AUC), calibration curves, the 30 Hosmer-Lemeshow test, and decision curve analysis. Comparisons between nomograms were 31 conducted using the net reclassification improvement (NRI) and integrated discrimination 32 improvement (IDI) indices.

33 **Results:** Nomogram¹ was established based on independent risk factors, including gender, Tibetan 34 ethnicity, age, incomplete right bundle branch block (IRBBB), atrial fibrillation (AF), sinus 35 tachycardia (ST), and T wave changes (TC). The AUCs for Nomogram¹ were 0.716 in the derivation set and 0.718 in the validation set. Nomogram^{II} was established based on independent 36 37 risk factors, including Tibetan ethnicity, age, right axis deviation (RAD), high voltage in the right 38 ventricle (HVRV), IRBBB, AF, pulmonary P waves, ST, and TC. The AUCs for Nomogram^{II} were 39 0.844 in the derivation set and 0.801 in the validation set. Both nomograms demonstrated 40 satisfactory clinical consistency. The IDI and NRI indices confirmed that Nomogram^{II} 41 outperformed Nomogram^I. Therefore, the online dynamic Nomogram^{II} was established.

42 **Conclusions**: A reliable and straightforward nomogram was developed to predict the risks of PH

43 in the plateau population.

44

45 Introduction

46	Pulmonary hypertension (PH) is a chronic, progressive condition characterised by elevated
47	pulmonary arterial pressure, primarily resulting from pulmonary vascular remodelling. This
48	remodelling is driven by the infiltration of inflammatory cells, endothelial-to-mesenchymal
49	transition, and hyperplasia of the pulmonary intima (Rubin & Naeije, 2023; Shah, Beckmann,
50	Vorla, & Kalra, 2023; Simonneau et al., 2019). PH often presents similarly to other lung diseases,
51	leading to diagnostic delays and, consequently, delays in receiving optimal treatment.
52	Approximately 1% of the adult population and more than half of individuals with congestive heart
53	failure are affected by PH (Hoeper et al., 2016; Mandras, Mehta, & Vaidya, 2020). Moreover, as
54	the pulmonary vascular load increases, PH can ultimately lead to life-threatening right heart
55	failure. The 1-year and 3-year survival rates for patients with PH range from 68% to 93% and 39%
56	to 77%, respectively (Naeije, Richter, & Rubin, 2022; Ruopp & Cockrill, 2022).
56 57	to 77%, respectively (Naeije, Richter, & Rubin, 2022; Ruopp & Cockrill, 2022). Right-heart catheterisation (RHC) is recognised as the gold standard for diagnosing PH,
57	Right-heart catheterisation (RHC) is recognised as the gold standard for diagnosing PH,
57 58	Right-heart catheterisation (RHC) is recognised as the gold standard for diagnosing PH, clarifying the specific diagnosis, and determining the severity of the condition. However, due to its
57 58 59	Right-heart catheterisation (RHC) is recognised as the gold standard for diagnosing PH, clarifying the specific diagnosis, and determining the severity of the condition. However, due to its invasive nature, RHC is not suitable as a widespread population screening tool for PH (McGoon et
57 58 59 60	Right-heart catheterisation (RHC) is recognised as the gold standard for diagnosing PH, clarifying the specific diagnosis, and determining the severity of the condition. However, due to its invasive nature, RHC is not suitable as a widespread population screening tool for PH (McGoon et al., 2004). Transthoracic echocardiography (TTE), a non-invasive screening test, is extensively
57 58 59 60 61	Right-heart catheterisation (RHC) is recognised as the gold standard for diagnosing PH, clarifying the specific diagnosis, and determining the severity of the condition. However, due to its invasive nature, RHC is not suitable as a widespread population screening tool for PH (McGoon et al., 2004). Transthoracic echocardiography (TTE), a non-invasive screening test, is extensively used for PH because it can provide estimates of pulmonary arterial systolic pressure (sPAP) and
57 58 59 60 61 62	Right-heart catheterisation (RHC) is recognised as the gold standard for diagnosing PH, clarifying the specific diagnosis, and determining the severity of the condition. However, due to its invasive nature, RHC is not suitable as a widespread population screening tool for PH (McGoon et al., 2004). Transthoracic echocardiography (TTE), a non-invasive screening test, is extensively used for PH because it can provide estimates of pulmonary arterial systolic pressure (sPAP) and evaluates cardiac structure and function. A clinical study involving 731 patients in China found no

66	According to literature reviews, nearly 140 million individuals reside in high-altitude regions
67	(altitudes exceeding 2,500 meters), and the number of people visiting these areas for economic or
68	recreational reasons has been increasing over the past few decades (Moore, Niermeyer, &
69	Zamudio, 1998; West, 2012; Xu & Jing, 2009). High altitude typically signifies a hypoxic
70	environment due to the decrease in barometric pressure as altitude increases, which proportionally
71	reduces PO2, resulting in hypobaric hypoxia (Gassmann et al., 2021). PH arising from prolonged
72	exposure to hypoxic conditions at high altitudes is termed high-altitude pulmonary hypertension
73	(Xu & Jing, 2009). Hypoxia triggers hypoxic pulmonary vasoconstriction (HPV), a physiological
74	response aimed at optimising ventilation/perfusion matching by redirecting blood to
75	better-oxygenated segments of the lung through the constriction of small pulmonary arteries
76	(Dunham-Snary et al., 2017). Furthermore, sustained hypoxia leads to pulmonary vascular
77	remodelling, increasing resistance to blood flow due to reduced vessel elasticity and decreased
78	vessel diameter. HPV and vascular remodelling are the primary mechanisms underlying
79	hypoxia-induced PH, which significantly impairs right ventricular function and can ultimately
80	result in fatal heart failure (Julian & Moore, 2019; Penaloza & Arias-Stella, 2007). Consequently,
81	there is a pressing need for a straightforward and dependable model to assist clinicians and
82	individuals in assessing the risk of PH in populations at high altitudes.
83	In this study, we developed and validated two risk prediction models for high-altitude PH

84 based on TTE results by examining routine inspection parameters in Tibet, China.

85

86 Materials and methods

87 Study population and data collection

88	Upon gathering data from all patients who underwent both TTE and 12-lead
89	electrocardiogram (ECG) examinations at the General Hospital of Tibet Military Command
90	between April 2021 and October 2023, we further screened the records based on the following
91	criteria: (1) age > 14 years; (2) interval between the TTE and ECG examinations < 2 months, and
92	(3) for patients with multiple TTE and/or ECG records, only the examination with the shortest
93	interval between TTE and ECG was selected. Ultimately, we compiled examination data for 6,603
94	eligible patients.

95	The retrospectively-collected clinical data were categorised into two main groups: (1)
96	demographic characteristics, including name, age, gender, and Tibetan ethnicity; (2) ECG results,
97	encompassing right axis deviation (RAD), clockwise rotation (CR), counterclockwise rotation
98	(CCR), high voltage in the right ventricle (HVRV), incomplete right bundle branch block
99	(IRBBB), complete right bundle branch block (CRBBB), atrial fibrillation (AF), sinus arrhythmia
100	(SA), sinus bradycardia (SB), sinus tachycardia (ST), T wave changes (TC), ST-segment changes
101	(STC), atrial premature beats (APB), ventricular premature beats (VPB), junctional premature
102	beats (JPB), complete left bundle branch block (CLBBB), first-degree atrioventricular block
103	(IAB), and pulmonary P waves (PP); (3) TTE results: pulmonary arterial systolic pressure (sPAP)
104	was measured via TTE to evaluate PH. PH was graded as follows: Grade I PH (50 mmHg $>$ sPAP
105	\geq 30 mmHg), Grade II PH (70 mmHg > sPAP \geq 50 mmHg), and Grade III PH (sPAP \geq 70
106	mmHg). The severity of PH increases with its grade, indicating a higher risk of the condition.
107	All procedures were conducted following the approval of the Ethics Committee of the
108	General Hospital of Tibet Military Command (APPROVAL NUMBER: 2024-KD002-01).
109	Subsequently, the data from all participants were anonymised and de-identified prior to analysis.

110 Consequently, the requirement for informed consent was waived.

111


- 112 Statistical analysis
- 113
- 114 Statistical analysis was performed with R software version 4.3.2. P < 0.05 (double-tailed)
- 115 was considered statistically significant.

For validation and derivation of the prediction model, subjects were divided into a validation set and a derivation set randomly, at a ratio of 7:3, respectively. Categorical variables were transformed into dichotomous variables, and continuous variables were expressed by concrete values (means \pm standard deviation) and analysed using Student's t-test. Fisher's exact test or Pearson's χ^2 test was applied for categorical variables.

121 The derivation set was used to select optimal predictive factors through the least absolute 122 shrinkage and selection operator (LASSO) regression technique. Independent factors were 123 identified via multivariate logistic regression analysis, incorporating variables selected during the 124 LASSO regression. A backward step-down selection process, guided by the Akaike information 125 criterion, determined the final model. The predictive accuracy of the nomograms was assessed 126 using the AUC of the ROC curve in both the derivation and validation sets. The 127 Hosmer-Lemeshow test and calibration curves were employed to evaluate the consistency between 128 actual outcomes and predicted probabilities. The clinical utility of the nomograms was assessed 129 through decision curve analysis (DCA). The cut-off value for the total score in the nomogram was 130 established based on the ROC curve, with patients categorised into low-risk and high-risk groups. 131 The performance comparison between nomograms was analysed using the integrated

132 discrimination improvement (IDI) and net reclassification improvement (NRI).





136	Figure 1. Flow diagram. Based on the exclusion and inclusion criteria, 6,603 patients were
137	included in this study. Patients were divided into a validation set and a derivation set randomly
138	following a 7:3 ratio. pulmonary hypertension, PH; right axis deviation, RAD; high voltage in the
139	right ventricle, HVRV; incomplete right bundle branch block, IRBBB; atrial fibrillation, AF; sinus
140	tachycardia, ST; T wave changes, TC; Pulmonary P waves, PP.
141	
142	Results

Table 1. Baseline characteristics of individuals in the derivation and validation
 sets

Variable	Variable Derivation set (n = 4622)		ahle		Р
Age					
Total (Mean ± SD)	42.43 ± 16.93	42.05 ± 16.41	0.390		
Age≤42, n (%)	2619(56.66)	1135(57.29)			
Age > 42, n (%)	2003(43.34)	846(42.71)	0.635		
Tibetan, n (%)			0.538		
No	2856 (61.79)	1240 (62.59)			
Yes	1766 (38.21)	741 (37.41)			
Gender, n (%)			0.260		
female	1219 (26.37)	549 (27.71)			
Gender, n (%)			0.26		

male	3403 (73.63)	1432 (72.29)	
RAD, n (%)			0.141
No	3833 (82.93)	1672 (84.40)	
Yes	789 (17.07)	309 (15.60)	
CR, n (%)			0.387
No	4000 (86.54)	1730 (87.33)	
Yes	622 (13.46)	251 (12.67)	
CCR, n (%)			0.402
No	3994 (86.41)	1727 (87.18)	
Yes	628 (13.59)	254 (12.82)	
HVRV, n (%)			0.102
No	4151 (89.81)	1805 (91.12)	
Yes	471 (10.19)	176 (8.88)	
IRBBB, n (%)			0.573
No	4547 (98.38)	1945 (98.18)	
Yes	75 (1.62)	36 (1.82)	
CRBBB, n (%)			0.945
No	4444 (96.15)	1904 (96.11)	
Yes	178 (3.85)	77 (3.89)	

AF, n (%)

0.594

No	4551 (98.46)	1954 (98.64)	
Yes	71 (1.54)	27 (1.36)	
SA, n (%)			0.243
No	4247 (91.89)	1837 (92.73)	
Yes	375 (8.11)	144 (7.27)	
ST, n (%)			0.910
No	4395 (95.09)	1885 (95.15)	
Yes	227 (4.91)	96 (4.85)	
SB, n (%)			0.345
No	4245 (91.84)	1833 (92.53)	
Yes	377 (8.16)	148 (7.47)	
TC, n (%)			0.769
No	4003 (86.61)	1721 (86.88)	
Yes	619 (13.39)	260 (13.12)	
STC, n (%)			0.415
No	4399 (95.18)	1876 (94.70)	
Yes	223 (4.82)	105 (5.30)	
APB, n (%)			0.219
No	4587 (99.24)	1960 (98.94)	
Yes	35 (0.76)	21 (1.06)	

JPB, n (%)			0.425
No	4603 (99.59)	1970 (99.44)	
Yes	19 (0.41)	11 (0.56)	
VPB, n (%)			0.844
No	4580 (99.09)	1962 (99.04)	
Yes	42 (0.91)	19 (0.96)	
PP, n (%)			0.439
No	4507 (97.51)	1938 (97.83)	
Yes	115 (2.49)	43 (2.17)	
CLBBB, n (%)			0.757
No	4610 (99.74)	1975 (99.70)	
Yes	12 (0.26)	6 (0.30)	
IAB, n (%)			0.910
No	4556 (98.57)	1952 (98.54)	
Yes	66 (1.43)	29 (1.46)	
PH \geq I grade, n (%)			0.820
No	2793 (60.43)	1203 (60.73)	
Yes	1829 (39.57)	778 (39.27)	
PH ≥ II grade, n(%)			0.962
No	4227 (91.45)	1811 (91.42)	

	Yes	395 (8.55)	170 (8.58)
146 147 148	Subjects' characteristics		
149	Following a 7:3 allocation	on ratio, 4,622 subjects were p	placed in the derivation set and 1,981
150	subjects in the validation set.	The characteristics of the su	bjects are presented in Table 1. The
151	prevalence of PH of Grade I or	higher was 39.57% (1,829 ca	uses) in the derivation set and 39.27%
152	(778 cases) in the validation se	t (P= $0.820 > 0.05$). The preva	ence of PH of Grade II or higher was
153	8.55% (395 cases) in the deriv	vation set and 8.58% (170 ca	ses) in the validation set (P= 0.962 >
154	0.05). No significant differenc	e was observed in the age dis	tribution between the derivation and
155	validation sets (42.43 \pm 16.93	vs. 42.05 ± 16.41, P=0.390 >	0.05), with age categorised into ≤ 42
156	and >42 subgroups based on the	he mean age. The composition	n ratios of the two age subgroups did
157	not significantly differ between	the validation and derivation	sets (P=0.6352 > 0.05). Furthermore,
158	no significant differences were	e observed in the characterist	ics related to gender, Tibetan or not,
159	RAD, CR, CCR, HVRV, IRBB	B, CRBBB, AF, SA, ST, SB,	TC, STC, APB, VPB, JPB, PP, IAB,
160	and CLBBB. (Table 1)		
161			
162	Independent risk factors	in PH≥I grade group and PH	≥II grade group
163			
164	In the PH≥I grade group	, based on the λ _min criterior	in the LASSO regression model, 18
165	out of 22 variables were selec	cted. However, this selection	was deemed excessive for practical
166	clinical applications. Therefore	e, we further refined the mo	del using the λ_1 se criterion, which
167	reduced the number of variable	es, albeit with a significant de	crease in the AUC of the ROC curve
168	$(\lambda_1 se)$ compared to the ROC of	curve (λ_min) (Fig. 2 C, E, G)). Ultimately, 9 variables were chosen

169	according to λ_1s	se, including	gender, Tib	etan ethnicity,	age ≤42,	age >42 ,	IRBBB,	CRBBB,	AF,

- 170 ST, and TC (Fig. 2 I). Gender, Tibetan ethnicity, age, IRBBB, AF, ST, and TC were subsequently
- 171 identified as independent risk factors for PH≥I grade through multivariate logistic regression
- analysis and were used to develop Nomogram^I. (Table 2)
- 173 In the PH>II grade group, based on the λ_1 se criterion in the LASSO regression model (Fig.
- 174 2 D, F), 11 variables were selected to align with clinical needs. These variables were Tibetan
- 175 ethnicity, age ≤42, age >42, RAD, HVRV, IRBBB, CRBBB, AF, PP, ST, and TC (Fig. 2 J).
- 176 Tibetan ethnicity, age, RAD, HVRV, IRBBB, AF, PP, ST, and TC were determined to be
- 177 independent risk factors for PH≥II grade through multivariate logistic regression analysis and
- 178 were utilised to construct Nomogram^{II}. (Table 3).
- 179


Variable	β -Coefficient	OR (95%CI)	Р
Tibetan	0.34	1.40 (1.23-1.60)	<0.001
Gender	-0.3	0.74 (0.65-0.84)	<0.001
Age	0.034	1.03 (1.03-1.04)	< 0.001
IRBBB	1.106	3.02 (1.96-4.67)	< 0.001
AF	1.431	4.18 (2.19-7.97)	<0.001
ST	0.369	1.45 (1.14-1.84)	0.003
ТС	0.306	1.36 (1.16-1.59)	< 0.001

180 **Table 2. Risk factors for PH≥I grade in the derivation set**

181

182 Table 3. Risk factors for PH≥II grade in the derivation set

Variable	β -Coefficient	OR (95%CI)	Р
Tibetan	0.689	1.99 (1.55-2.57)	< 0.001
Age	0.042	1.04 (1.03-1.05)	<0.001
RAD	0.751	2.12 (1.56-2.88)	<0.001
HVRV	0.486	1.63 (1.14-2.31)	0.007
IRBBB	1.512	4.53 (2.77-7.42)	<0.001
AF	2.102	8.18 (5.13-13.05)	<0.001
ST	1.247	3.48 (2.58-4.70)	<0.001
TC	0.592	1.81 (1.44-2.27)	<0.001
РР	1.486	4.42 (2.96-6.61)	<0.001



186 Figure 2 illustrates the optimal predictive variables as determined by the LASSO binary
187 logistic regression model. Panels A and B depict the measurement of tricuspid regurgitation

188	spectra via transthoracic echocardiography in patients with Grade I PH (A) and Grade III PH (B).
189	Panels C to J demonstrate the identification of the optimal penalisation coefficient lambda (λ) in
190	the LASSO model using 10-fold cross-validation for the PH≥I grade group (C) and the PH≥II
191	grade group (D). The dotted line on the left (λ _min) represents the value of the harmonic
192	parameter $log(\lambda)$ at which the model's error is minimised, and the dotted line on the right (λ_1 se)
193	indicates the value of the harmonic parameter $log(\lambda)$ at which the model's error is minimal minus 1
194	standard deviation. The LASSO coefficient profiles of 22 predictive factors for the PH≥I grade
195	group (E) and the PH≥II grade group (F) show that as the value of λ decreased, the degree of
196	model compression increased, enhancing the model's ability to select significant variables. ROC
197	curves were constructed for three models (LASSO, LASSO- λ _min, LASSO- λ _1se) in both the PH
198	≥I grade group (G) and the PH≥II grade group (H). Histograms depict the final variables selected
199	according to λ_1 se and their coefficients for the PH≥I grade group (I) and the PH≥II grade group
200	(J). Asterisks denote levels of statistical significance: $*P < 0.05$, $**P < 0.01$, $***P < 0.001$.
201	
202	Construction of Nomogram ¹ in PH \geq I grade group and Nomogram ¹¹ in PH \geq II grade group
203	
204	In the PH \geq I grade group, a predictive Nomogram ^I for PH \geq I grade was developed based on
205	independent risk factors, including gender, Tibetan ethnicity, age, IRBBB, AF, ST, and TC. Points
206	are assigned to each independent factor by drawing a vertical line to the points scale. The total
207	points for an individual correspond to their risk of developing PH. Patients were then classified
208	into high-risk and low-risk subgroups according to the total score's cut-off value (cut-off value:
209	45), which was determined based on the ROC curve (Fig. 3 A). The risks for the two groups were
210	evaluated in both the derivation and validation sets. In the derivation set, the risk of PH in the

211	high-risk group was significantly higher than in the low-risk group (odds ratio [OR]: 4.210, 95%
212	confidence interval [CI]: 3.715-4.775) (Fig. 3 B), as was also observed in the validation set (odds
213	ratio [OR]: 4.207, 95% confidence interval [CI]: 3.476-5.102) (Fig. 3 C).
214	In the PH≥II grade group, a predictive Nomogram ^{II} for PH≥II grade was developed using
215	independent risk factors, including Tibetan ethnicity, age, RAD, HVRV, IRBBB, AF, PP, ST and
216	TC. Based on the cut-off value of the total score (cut-off value: 76), determined in line with the
217	ROC curve, patients were categorised into high-risk and low-risk subgroups (Fig. 3 D). The risks
218	for the two groups were evaluated in both the derivation and validation sets. In the derivation set,
219	the risk of PH in the high-risk group was significantly greater than in the low-risk group (odds
220	ratio [OR]: 11.591, 95% confidence interval [CI]: 9.128-14.845) (Fig. 3 E), a finding that was
221	replicated in the validation set (odds ratio [OR]: 7.103, 95% confidence interval [CI]: 5.106-9.966)
222	(Fig. 3 F)
223	






Figure 3. Nomogram for predicting PH and risk stratification based on total score. (A-C)
Nomogram^I for the prediction of PH≥I grade in the PH≥I grade group. Points for each
independent factor are summed to calculate total points, determining the corresponding 'risk' level.

229	Patients were divided into 'High-risk' and 'Low-risk' subgroups according to the cutoff of the total
230	points (A). Histograms illustrate the odds ratio (OR) comparing the 'High-risk' group to the
231	'Low-risk' group in the derivation set (B) and validation set (C). (D-F) Nomogram ^{II} for predicting
232	PH≥II grade within the PH≥II grade group: Similarly, points from each independent factor are
233	totalled, and the corresponding 'risk' level is ascertained. Patients are divided into 'High-risk' and
234	'Low-risk' groups based on the cut-off value of the total points (D). Histograms display the OR for
235	the 'High-risk' group compared to the 'Low-risk' group in the derivation (E) and validation set (F).
236	*** $P < 0.001$. (G) Screenshot of dynamic Nomogram ^{II} 's web page.





Figure 4. Receiver operating characteristic (ROC) curves and area under the curve (AUC)
for Nomogram^I in PH≥I and Nomogram^{II} in PH≥II grade groups. (A-F) In the PH≥I grade group,
the ROC and corresponding AUC of Nomogram^I and independent factors in the derivation set

242 (A-C) and validation set (D-F). (G-L) In the PH≥II grade group, the ROC and corresponding AUC



244





Figure 5. Calibration plots and Hosmer-Lemeshow test results for Nomogram^I in PH \geq I and Nomogram^{II} in PH \geq II grade groups. (A-B) In the PH \geq I grade group, the calibration plots of Nomogram^{II} in the derivation set (A) and the validation set (B). (C-D) In the PH \geq II grade group,

249	the calibration plots of Nomogram ^{II} in the derivation set (C) and the validation set (D). (E) In the
250	PH≥I grade group, Hosmer-Lemeshow test results for Nomogram ^I in the derivation set and the
251	validation set. (F) In the PH≥II grade group, Hosmer-Lemeshow test results for Nomogram ^{II} in the
252	derivation set and the validation set.
253	
254	Assessment and validation of $Nomogram^{I}$ in the $PH \ge I$ grade group and $Nomogram^{II}$ in the
255	PH≥II grade group
256	
257	In the PH≥I grade group, Nomogram ^I was developed to predict the risk of PH≥I grade,
258	utilising the AUC to assess its discriminative ability. The AUC value for Nomogram ^I was 0.716
259	(95% confidence interval [CI]: 0.701 - 0.731) in the derivation set (Fig 4. A) and 0.718 (95%
260	confidence interval [CI]: 0.695 - 0.741) in the validation set (Fig 4. D). Furthermore, ROC curves
261	were used to compare the discriminative capacity of Nomogram ^I and single independent factors in
262	predicting PH \geq I grade. Notably, the AUC of Nomogram ^I was significantly higher than that of any
263	single independent factor in the derivation (Fig 4. B, C) and the validation set (Fig 4. E, F). The
264	calibration curves for the derivation set (Fig 5. A) and the validation set (Fig 5. B) demonstrated
265	high agreement between predicted and actual values, indicating that Nomogram ^I accurately
266	predicts PH≥I grade. The results of the Hosmer-Lemeshow test in both the derivation set
267	(P=0.109 > 0.05) and the validation set $(P=0.317 > 0.05)$ further confirmed the effective
268	performance of Nomogram ^I (Fig 5. E).
269	Nomogram ^{II} was developed to predict the risk of PH≥II grade. The AUC for Nomogram ^{II}
270	was 0.844 (95% confidence interval [CI]: 0.823 - 0.865) in the derivation set (Fig 4. G) and 0.801

271 (95% confidence interval [CI]: 0.763 - 0.838) in the validation set (Fig 4. J). Furthermore, ROC

272	curves were used to compare the discriminative capacity of Nomogram ^{II} and individual
273	independent factors in predicting PH≥II grade. The AUC of Nomogram ^{II} was significantly higher
274	than that of any single independent factor in the derivation set (Fig 4. H, I) and the validation set
275	(Fig 4. K, L). The calibration curves for the derivation set (Fig 5. C) and the validation set (Fig 5.
276	D) demonstrated high agreement between the predicted and actual values, indicating that
277	Nomogram ^{II} accurately predicts PH≥II grade. Additionally, the results of the Hosmer-Lemeshow
278	test in the derivation set (P=0.377 > 0.05) and the validation set (P=0.127 > 0.05) further
279	confirmed the good performance of Nomogram ^{II} (Fig 5. F).
280 281 282	Clinical utility of Nomogram ¹ and Nomogram ¹¹
283	In the PH≥I grade group, the clinical utility of Nomogram ^I for predicting the risk of PH≥I
284	and and set of the DCA. This and this area lade size if and not have fit with a threshold
	grade was assessed using DCA. This analysis revealed a significant net benefit with a threshold
285	probability range of 20% to 91% in the derivation set (Fig 6. A) and 14% to 74% in the validation
285 286	
	probability range of 20% to 91% in the derivation set (Fig 6. A) and 14% to 74% in the validation
286	probability range of 20% to 91% in the derivation set (Fig 6. A) and 14% to 74% in the validation set (Fig 6. B). Moreover, the DCA curve from the derivation set indicated that the clinical
286 287	probability range of 20% to 91% in the derivation set (Fig 6. A) and 14% to 74% in the validation set (Fig 6. B). Moreover, the DCA curve from the derivation set indicated that the clinical predictive capability of Nomogram ^I surpassed that of any single independent factor, a finding that
286 287 288	probability range of 20% to 91% in the derivation set (Fig 6. A) and 14% to 74% in the validation set (Fig 6. B). Moreover, the DCA curve from the derivation set indicated that the clinical predictive capability of Nomogram ^I surpassed that of any single independent factor, a finding that

- range of 1% to 70% in the derivation set (Fig 6. E) and 1% to 82% in the validation set (Fig 6. F).
- 293 Additionally, the DCA curve for the derivation set demonstrated that the clinical predictive
- 294 effectiveness of Nomogram^{II} exceeded that of any single independent factor, a conclusion that was



295 also confirmed in the validation set (Fig 6. G, H).



Figure 6. Decision curve analysis (DCA) for Nomogram^I in the PH≥I grade and Nomogram^{II} 299 300 in the PH≥II grade group. (A-D) In the PH≥I grade group, the DCAs of Nomogram^I and 301 independent factors in the derivation (A, C) and validation set (B, D). (E-H) In the PH≥II grade

- 302 group, the DCAs of Nomogram^{II} and independent factors in the derivation (E, G) and validation
- 303 set (F, H).
- 304
- 305 *Comparison between Nomogram^I and Nomogram^{II}*
- 306 In the PH≥I grade group, when comparing Nomogram^I to Nomogram^{II}, Nomogram^I exhibited
- 307 an IDI of -0.0012 (95% CI: -0.0032 to 0.0009, p=0.2777), a categorical NRI of 0.0117 (95% CI:
- 308 -0.0004 to 0.0237, p=0.0575), and a continuous NRI of -0.2423 (95% CI: -0.2992 to -0.1854,
- 309 p<0.001) in predicting the risk of PH≥I grade.
- 310 In the PH≥II grade group, compared to Nomogram^{II}, Nomogram^{II} demonstrated an IDI of
- 311 0.0366 (95% CI: 0.0247 to 0.0485, p<0.001), a categorical NRI of 0.0301 (95% CI: 0.0093 to
- 312 0.0510, p<0.05), and a continuous NRI of 0.2785 (95% CI: 0.1824 to 0.3745, p<0.001) for
- 313 predicting the risk of PH≥II grade.
- These results indicate that Nomogram^{II} outperformed Nomogram^I in terms of IDI and NRI
- 315 values.
- 316 Website of Nomogram^{II}
- Patients and physicians can calculate the risk of pulmonary hypertension through a free
 web-based dynamic Nomogram^{II} (<u>https://dapeng.shinyapps.io/dynnomapp-1/</u>), and the screenshot
 of dynamic Nomogram^{II}'s web page was shown (Fig 3. G).

320

321 Discussion

322 A significant portion of the global population lives in high-altitude areas such as the Tibetan

323 Plateau, Ethiopian Highlands, Andes Mountains, and Pamir Plateau. These regions are marked by

324	an extremely hypoxic environment that leads to alveolar hypoxia, posing severe risks to the
325	cardiopulmonary system. One such risk is the development of PH, which occurs through
326	mechanisms like hypoxic pulmonary vasoconstriction and pulmonary vascular remodelling
327	(Burtscher, Gatterer, Burtscher, & Mairbäurl, 2018; Sydykov et al., 2021; Wilkins, Ghofrani,
328	Weissmann, Aldashev, & Zhao, 2015). Accurate, timely diagnosis and early, effective treatment
329	are crucial for the clinical improvement and survival of patients with PH. Without prompt
330	intervention, PH can impair right heart function and ultimately result in fatal right heart failure
331	(Benza et al., 2010; Kim & George, 2019; McGoon et al., 2004). Thus, there is a need to develop a
332	predictive model to estimate the risk of PH, facilitating risk stratification and management. In this
333	study, we analysed routine electrocardiogram examination indicators and basic demographic
334	information to assess the risk of PH. We developed nomograms for the PH≥I grade group and the
335	PH≥II grade group, and the performance of these nomograms was evaluated and validated.
335 336	PH≥II grade group, and the performance of these nomograms was evaluated and validated. Currently, TTE is widely utilised for large-scale, non-invasive screening of patients at risk for
336	Currently, TTE is widely utilised for large-scale, non-invasive screening of patients at risk for
336 337	Currently, TTE is widely utilised for large-scale, non-invasive screening of patients at risk for PH (D'Alto et al., 2018; Habib & Torbicki, 2010; Janda, Shahidi, Gin, & Swiston, 2011). However,
336 337 338	Currently, TTE is widely utilised for large-scale, non-invasive screening of patients at risk for PH (D'Alto et al., 2018; Habib & Torbicki, 2010; Janda, Shahidi, Gin, & Swiston, 2011). However, in plateau regions such as Tibet, medical resources are relatively limited, and remote villages and
336 337 338 339	Currently, TTE is widely utilised for large-scale, non-invasive screening of patients at risk for PH (D'Alto et al., 2018; Habib & Torbicki, 2010; Janda, Shahidi, Gin, & Swiston, 2011). However, in plateau regions such as Tibet, medical resources are relatively limited, and remote villages and towns lack the facilities for TTE examinations. ECG examinations, being easy to administer,
336 337 338 339 340	Currently, TTE is widely utilised for large-scale, non-invasive screening of patients at risk for PH (D'Alto et al., 2018; Habib & Torbicki, 2010; Janda, Shahidi, Gin, & Swiston, 2011). However, in plateau regions such as Tibet, medical resources are relatively limited, and remote villages and towns lack the facilities for TTE examinations. ECG examinations, being easy to administer, cost-effective, and feasible for remote delivery through telemedicine, offer a practical alternative
336 337 338 339 340 341	Currently, TTE is widely utilised for large-scale, non-invasive screening of patients at risk for PH (D'Alto et al., 2018; Habib & Torbicki, 2010; Janda, Shahidi, Gin, & Swiston, 2011). However, in plateau regions such as Tibet, medical resources are relatively limited, and remote villages and towns lack the facilities for TTE examinations. ECG examinations, being easy to administer, cost-effective, and feasible for remote delivery through telemedicine, offer a practical alternative (Ismail, Jovanovic, Ramzan, & Rabah, 2023). A retrospective analysis has demonstrated that ECG
336 337 338 339 340 341 342	Currently, TTE is widely utilised for large-scale, non-invasive screening of patients at risk for PH (D'Alto et al., 2018; Habib & Torbicki, 2010; Janda, Shahidi, Gin, & Swiston, 2011). However, in plateau regions such as Tibet, medical resources are relatively limited, and remote villages and towns lack the facilities for TTE examinations. ECG examinations, being easy to administer, cost-effective, and feasible for remote delivery through telemedicine, offer a practical alternative (Ismail, Jovanovic, Ramzan, & Rabah, 2023). A retrospective analysis has demonstrated that ECG examination results correlate with clinical parameters reflecting the severity of PH (Michalski et

346 relevant treatment.

347	In this study, based on sPAP assessed by TTE examination, patients at risk of PH were
348	classified into grades I-III. We developed and validated two nomograms for the PH≥I grade group
349	(Nomogram ^I) and the PH≥II grade group (Nomogram ^{II}), with ECG examination results serving as
350	the primary component for both. Nomogram ^I included seven variables: gender, Tibetan ethnicity,
351	age, IRBBB, AF, ST, and TC. Nomogram ^{II} incorporated nine variables: Tibetan ethnicity, age,
352	RAD, HVRV, IRBBB, AF, PP, ST, and TC (Fig 3. A, D). These variables are readily available
353	from routine ECG examinations. Additionally, patients were categorised into high-risk and
354	low-risk groups based on the cut-off value of the total score in the nomogram, with the OR value
355	for the high-risk group being significantly higher than that of the low-risk group (Fig 3). Therefore,
356	both nomograms offer a useful and straightforward method for in-depth evaluation, even without
357	medical professional intervention. Both Nomogram ^{II} and Nomogram ^{II} demonstrated good
358	calibration and clinical utility (Fig 5, 6), though ROC analysis revealed that the AUC for
359	Nomogram ^{II} was higher than that for Nomogram ^I (0.844 vs 0.716). IDI and NRI are recognised
360	indicators that describe improved accuracy in predicting binary, multi-classification, or survival
361	outcomes (Wang, Cheng, Seaberg, & Becker, 2020). In a similar vein to a 10-year retrospective
362	cohort study, which constructed two nomograms for hypertension risk prediction and compared
363	them using IDI and NRI values (Deng et al., 2021), we used IDI and NRI to evaluate the
364	performance of Nomogram ^{II} and Nomogram ^{II} . Our findings indicated no significant difference
365	between Nomogram ^{II} and Nomogram ^{II} in the PH \geq I grade group; however, Nomogram ^{II} exhibited
366	superior performance compared to Nomogram ^I in the PH≥II grade group, thus demonstrating its
367	enhanced predictive capability. So, we created an online dynamic Nomogram II for doctors and

368 patients to calculate the risk of PH (Fig 3. G).

369	In this study, age and Tibetan ethnicity were identified as independent predictors of PH, a
370	finding that aligns with conclusions from a single-centre, cross-sectional study among native
371	Tibetans in Sichuan Province, China (Gou et al., 2020). We hypothesise that this association may
372	be due to the longer exposure to the hypoxic environment at high altitudes experienced by older
373	individuals and Tibetans, promoting hypoxic contraction of pulmonary blood vessels and
374	subsequent pulmonary vascular remodelling, thereby leading to PH. Additionally, the occurrence
375	of AF emerged as an independent predictor of PH with the highest OR values in both nomograms
376	(Table 2, 3). PH is known to be characterised by pulmonary vascular remodelling, which can
377	induce fibrosis and excessive myocardial apoptosis, ultimately contributing to AF (Yi et al., 2023),
378	a finding that corroborates our results. Nonetheless, it was observed that no single predictor alone
379	was effective in distinguishing PH, exhibiting poor clinical utility compared to the comprehensive
380	approach offered by the nomogram (Fig 4, Fig 6).
381	Our study has several limitations. Firstly, TTE serves only as a screening method for PH and
382	is not the gold standard; its results merely indicate the risk of PH in the examined individuals.
383	Secondly, given the constrained medical resources in remote areas, we primarily incorporated
384	readily ECG results and basic demographic information into the nomograms, resulting in a
385	relatively simple set of independent predictors. Lastly, the dataset for this study was exclusively
386	sourced from Tibet, China, meaning the validation of the nomograms lacks external validation
387	sets.

388 Conclusion

389 We have developed a reliable and straightforward nomogram to predict the risks associated

390	with PH, demonstrating satisfactory discrimination and calibration. Upon rigorous validation
391	using internal datasets, the nomogram has shown clinical utility and favourable predictive
392	accuracy. It is anticipated to serve as an effective and convenient clinical tool for assessing the risk
393	of PH in populations residing at high altitudes.
394	
395	Acknowledgements
396	This study was funded by the Talent Program of Army Medical University (No. 2019R038).
397	
398	Statements and Declarations
399	The authors have no conflict of interest.
400	
401	Data availability statement
401 402	Data availability statement Source data files have been provided.
402	
402 403	Source data files have been provided.
402 403 404 405 406	Source data files have been provided. References Benza, R. L., Miller, D. P., Gomberg-Maitland, M., Frantz, R. P., Foreman, A. J., Coffey, C. S.,
402 403 404 405 406 407	Source data files have been provided. References Benza, R. L., Miller, D. P., Gomberg-Maitland, M., Frantz, R. P., Foreman, A. J., Coffey, C. S., McGoon, M. D. (2010). Predicting survival in pulmonary arterial hypertension: insights from the
402 403 404 405 406 407 408	Source data files have been provided. References Benza, R. L., Miller, D. P., Gomberg-Maitland, M., Frantz, R. P., Foreman, A. J., Coffey, C. S., McGoon, M. D. (2010). Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management
402 403 404 405 406 407 408 409	Source data files have been provided. References Benza, R. L., Miller, D. P., Gomberg-Maitland, M., Frantz, R. P., Foreman, A. J., Coffey, C. S., McGoon, M. D. (2010). Predicting survival in pulmonary arterial hypertension: insights from the
402 403 404 405 406 407 408 409 410	Source data files have been provided. References Benza, R. L., Miller, D. P., Gomberg-Maitland, M., Frantz, R. P., Foreman, A. J., Coffey, C. S., McGoon, M. D. (2010). Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation, 122:164-172. doi:10.1161/circulationaha.109.898122
402 403 404 405 406 407 408 409	Source data files have been provided. References Benza, R. L., Miller, D. P., Gomberg-Maitland, M., Frantz, R. P., Foreman, A. J., Coffey, C. S., McGoon, M. D. (2010). Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management
402 403 404 405 406 407 408 409 410 411	Source data files have been provided. References Benza, R. L., Miller, D. P., Gomberg-Maitland, M., Frantz, R. P., Foreman, A. J., Coffey, C. S., McGoon, M. D. (2010). Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation, 122:164-172. doi:10.1161/circulationaha.109.898122 Burtscher, M., Gatterer, H., Burtscher, J., & Mairbäurl, H. (2018). Extreme Terrestrial
402 403 404 405 406 407 408 409 410 411 412	Source data files have been provided. References Benza, R. L., Miller, D. P., Gomberg-Maitland, M., Frantz, R. P., Foreman, A. J., Coffey, C. S., McGoon, M. D. (2010). Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation, 122:164-172. doi:10.1161/circulationaha.109.898122 Burtscher, M., Gatterer, H., Burtscher, J., & Mairbäurl, H. (2018). Extreme Terrestrial Environments: Life in Thermal Stress and Hypoxia. A Narrative Review. Front Physiol, 9:572.
402 403 404 405 406 407 408 409 410 411 412 413	Source data files have been provided. References Benza, R. L., Miller, D. P., Gomberg-Maitland, M., Frantz, R. P., Foreman, A. J., Coffey, C. S., McGoon, M. D. (2010). Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation, 122:164-172. doi:10.1161/circulationaha.109.898122 Burtscher, M., Gatterer, H., Burtscher, J., & Mairbäurl, H. (2018). Extreme Terrestrial Environments: Life in Thermal Stress and Hypoxia. A Narrative Review. Front Physiol, 9:572.
402 403 404 405 406 407 408 409 410 411 412 413 414	Source data files have been provided. References Benza, R. L., Miller, D. P., Gomberg-Maitland, M., Frantz, R. P., Foreman, A. J., Coffey, C. S., McGoon, M. D. (2010). Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation, 122:164-172. doi:10.1161/circulationaha.109.898122 Burtscher, M., Gatterer, H., Burtscher, J., & Mairbäurl, H. (2018). Extreme Terrestrial Environments: Life in Thermal Stress and Hypoxia. A Narrative Review. Front Physiol, 9:572. doi:10.3389/fphys.2018.00572
402 403 404 405 406 407 408 409 410 411 412 413 414 415	Source data files have been provided. References Benza, R. L., Miller, D. P., Gomberg-Maitland, M., Frantz, R. P., Foreman, A. J., Coffey, C. S., McGoon, M. D. (2010). Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation, 122:164-172. doi:10.1161/circulationaha.109.898122 Burtscher, M., Gatterer, H., Burtscher, J., & Mairbäurl, H. (2018). Extreme Terrestrial Environments: Life in Thermal Stress and Hypoxia. A Narrative Review. Front Physiol, 9:572. doi:10.3389/fphys.2018.00572 D'Alto, M., Bossone, E., Opotowsky, A. R., Ghio, S., Rudski, L. G., & Naeije, R. (2018).

419 Deng, X., Hou, H., Wang, X., Li, Q., Li, X., Yang, Z., & Wu, H. (2021). Development and 420 validation of a nomogram to better predict hypertension based on a 10-year retrospective cohort 421 study in China. Elife, 10. doi:10.7554/eLife.66419 422 423 Dunham-Snary, K. J., Wu, D., Sykes, E. A., Thakrar, A., Parlow, L. R. G., Mewburn, J. D., . . . 424 Archer, S. L. (2017). Hypoxic Pulmonary Vasoconstriction: From Molecular Mechanisms to 425 Medicine. Chest, 151: 181-192. doi:10.1016/j.chest.2016.09.001 426 427 Gassmann, M., Cowburn, A., Gu, H., Li, J., Rodriguez, M., Babicheva, A., . . . Zhao, L. (2021). 428 Hypoxia-induced pulmonary hypertension-Utilizing experiments of nature. Br J Pharmacol, 178: 429 121-131. doi:10.1111/bph.15144 430 431 Gou, Q., Shi, R., Zhang, X., Meng, Q., Li, X., Rong, X., . . . Chen, X. (2020). The Prevalence and 432 Risk Factors of High-Altitude Pulmonary Hypertension Among Native Tibetans in Sichuan 433 Province, China. High Alt Med Biol, 21: 327-335. doi:10.1089/ham.2020.0022 434 435 Habib, G., & Torbicki, A. (2010). The role of echocardiography in the diagnosis and management 436 of patients with pulmonary hypertension. Eur Respir Rev, 19: 288-299. 437 doi:10.1183/09059180.00008110 438 Hoeper, M. M., Humbert, M., Souza, R., Idrees, M., Kawut, S. M., Sliwa-Hahnle, K., . . . Gibbs, J. 439 S. (2016). A global view of pulmonary hypertension. Lancet Respir Med, 4: 306-322. 440 doi:10.1016/s2213-2600(15)00543-3 441 442 Hong, C., Chen, R., Hu, L., Liu, H., Lu, J., Zhuang, C., . . . Zheng, Z. (2023). Aetiological 443 distribution of pulmonary hypertension and the value of transthoracic echocardiography screening 444 in the respiratory department: A retrospective analysis from China. Clin Respir J, 17: 536-547. 445 doi:10.1111/crj.13623 446 447 Ismail, A. R., Jovanovic, S., Ramzan, N., & Rabah, H. (2023). ECG Classification Using an 448 Optimal Temporal Convolutional Network for Remote Health Monitoring. Sensors (Basel), 23: 449 doi:10.3390/s23031697 450 451 Janda, S., Shahidi, N., Gin, K., & Swiston, J. (2011). Diagnostic accuracy of echocardiography for 452 pulmonary hypertension: a systematic review and meta-analysis. Heart, 97: 612-622. 453 doi:10.1136/hrt.2010.212084 454 455 Julian, C. G., & Moore, L. G. (2019). Human Genetic Adaptation to High Altitude: Evidence from 456 the Andes. Genes (Basel), 10. doi:10.3390/genes10020150 457 458 Kim, D., & George, M. P. (2019). Pulmonary Hypertension. Med Clin North Am, 103: 413-423. 459 doi:10.1016/j.mcna.2018.12.002 460 461 Mandras, S. A., Mehta, H. S., & Vaidya, A. (2020). Pulmonary Hypertension: A Brief Guide for 462 Clinicians. Mayo Clin Proc, 95: 1978-1988. doi:10.1016/j.mayocp.2020.04.039

463	
464	McGoon, M., Gutterman, D., Steen, V., Barst, R., McCrory, D. C., Fortin, T. A., & Loyd, J. E.
465	(2004). Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP
466	evidence-based clinical practice guidelines. Chest, 126(1 Suppl), 14s-34s.
467	doi:10.1378/chest.126.1_suppl.14S
468	
469	Michalski, T. A., Pszczola, J., Lisowska, A., Knapp, M., Sobkowicz, B., Kaminski, K., &
470	Ptaszynska-Kopczynska, K. (2022). ECG in the clinical and prognostic evaluation of patients with
471	pulmonary arterial hypertension: an underestimated value. Ther Adv Respir Dis, 16:
472	17534666221087846. doi:10.1177/17534666221087846
473	
474	Moore, L. G., Niermeyer, S., & Zamudio, S. (1998). Human adaptation to high altitude: regional
475	and life-cycle perspectives. Am J Phys Anthropol, Suppl 27: 25-64.
476	doi:10.1002/(sici)1096-8644(1998)107:27+<25::aid-ajpa3>3.0.co;2-1
477	
478	Naeije, R., Richter, M. J., & Rubin, L. J. (2022). The physiological basis of pulmonary arterial
479	hypertension. Eur Respir J, 59. doi:10.1183/13993003.02334-2021
480	
481	Penaloza, D., & Arias-Stella, J. (2007). The heart and pulmonary circulation at high altitudes:
482	healthy highlanders and chronic mountain sickness. Circulation, 115: 1132-1146.
483	doi:10.1161/circulationaha.106.624544
484	
485	Rubin, L. J., & Naeije, R. (2023). Sotatercept for pulmonary arterial hypertension: something old
486	and something new. Eur Respir J, 61. doi:10.1183/13993003.01972-2022
487	
488	Ruopp, N. F., & Cockrill, B. A. (2022). Diagnosis and Treatment of Pulmonary Arterial
489	Hypertension: A Review. Jama, 327: 1379-1391. doi:10.1001/jama.2022.4402
490	
491	Shah, A. J., Beckmann, T., Vorla, M., & Kalra, D. K. (2023). New Drugs and Therapies in
492	Pulmonary Arterial Hypertension. Int J Mol Sci, 24. doi:10.3390/ijms24065850
493	
494	Simonneau, G., Montani, D., Celermajer, D. S., Denton, C. P., Gatzoulis, M. A., Krowka, M.,
495	Souza, R. (2019). Haemodynamic definitions and updated clinical classification of pulmonary
496	hypertension. Eur Respir J, 53. doi:10.1183/13993003.01913-2018
497	
498	Sydykov, A., Mamazhakypov, A., Maripov, A., Kosanovic, D., Weissmann, N., Ghofrani, H. A.,
499	Schermuly, R. T. (2021). Pulmonary Hypertension in Acute and Chronic High Altitude
500	Maladaptation Disorders. Int J Environ Res Public Health, 18. doi:10.3390/ijerph18041692
501	
502	Wang, Z., Cheng, Y., Seaberg, E. C., & Becker, J. T. (2020). Quantifying diagnostic accuracy
503	improvement of new biomarkers for competing risk outcomes. Biostatistics.
504	doi:10.1093/biostatistics/kxaa048
505	
506	West, J. B. (2012). High-altitude medicine. Am J Respir Crit Care Med, 186: 1229-1237.

507 doi:10.1164/rccm.201207-1323CI

- 508
- 509 Wilkins, M. R., Ghofrani, H. A., Weissmann, N., Aldashev, A., & Zhao, L. (2015).
- 510 Pathophysiology and treatment of high-altitude pulmonary vascular disease. Circulation, 131:
- 511 582-590. doi:10.1161/circulationaha.114.006977
- 512
- 513 Xu, X. Q., & Jing, Z. C. (2009). High-altitude pulmonary hypertension. Eur Respir Rev, 18: 13-17.
- 514 doi:10.1183/09059180.00011104
- 515
- 516 Yi, Y., Tianxin, Y., Zhangchi, L., Cui, Z., Weiguo, W., & Bo, Y. (2023). Pinocembrin attenuates
- 517 susceptibility to atrial fibrillation in rats with pulmonary arterial hypertension. Eur J Pharmacol,
- 518 960: 176169. doi:10.1016/j.ejphar.2023.176169

